



PRESSRELEASE

Report from the Annual General Meeting of PledPharma

Stockholm, May 7, 2019. The Annual General Meeting (AGM) of PledPharma AB (publ) was held on May 7, 2019, where the general meeting resolved in accordance with submitted proposals. The complete proposals are set out in the notice to the meeting.

The following resolutions were, i.a., passed at the AGM.

The AGM resolved to adopt the profit and loss statement and the balance sheet for the financial year 2018. The result for the year was set off against the share premium reserve and the remaining share premium reserve was carried forward.

The AGM resolved to discharge the Board of Directors and the managing director from liability for the financial year 2018.

The AGM decided that the Board of Directors shall consist of five ordinary members without deputies. Håkan Åström, Marie Ekström Trägårdh, Sten Nilsson, Gunilla Osswald and Elisabeth Svanberg were re-elected as directors. Håkan Åström was re-elected as chairman.

The AGM resolved that directors' fees shall be paid with a total amount of SEK 1 260 000. The chairman of the Board of Directors shall receive a fee of SEK 600 000 and the other directors shall receive fees of SEK 165 000 each. Fees to the auditor shall be paid as per approved invoice.

It was resolved, for the period until the end of the AGM 2020, to appoint the registered public accounting firm BDO Mälardalen AB as auditor. Jörgen Lövgren will continue as responsible auditor.

The nomination committee's proposal regarding principles for and the establishment of a nomination committee for the AGM 2020 was approved.

The Board of Directors' proposal regarding guidelines for the compensation of senior management was approved.

The AGM resolved to adopt new articles of association according to which the share capital shall be no less than SEK 2 500 000 and no more than SEK 10 000 000. In addition, the number of shares shall be no less than 47 500 000 and no more than 190 000 000.

Finally, the AGM resolved to authorize the Board of Directors to, for the period until the next AGM, to issue securities. The Board of Directors cannot, however, make resolutions with deviation from the shareholders' preferential rights resulting in a share capital increase of more than ten (10) per cent in relation to the share capital at the time when the authorization was utilized for the first time.

For further information, please contact:

Nicklas Westerholm, CEO

Tel. +46 (0)73 354 20 62

nicklas.westerholm@pledpharma.se

Yilmaz Mahshid, CFO

Tel. +46 (0)72 231 68 00

Yilmaz.mahshid@pledpharma.se

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project **PledOx**[®] is being developed to prevent nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate **Aladote**[®] is being developed to reduce the risk of acute liver injury associated with acetaminophen poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote[®] has been granted Orphan Drug Designation in the US. PledPharma (STO:PLED) is listed on Nasdaq First North. Erik Penser Bank acts Certified Adviser (www.penser.se). For further information, please see www.pledpharma.se